{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:00:15Z","timestamp":1770505215399,"version":"3.49.0"},"reference-count":12,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T00:00:00Z","timestamp":1346976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openrheumatologyjournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORJ"],"published-print":{"date-parts":[[2012,9,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The use of TNF-alpha antagonists may be associated with an increased rate of infections in risk populations of patients with RA. Our hypothesis was that in patients with a high risk of infection Rituximab (RTX) could be a safer alternative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We analyzed the outcome of RA patients who received RTX instead of TNF-alpha antagonist because of a history of serious infections or frequent infectious events. All patients in a given time period were included in the retrospective analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>32 patients were identified according to the above criteria and followedup for a mean period of 16 \u00b1 8 months (range 6 \u2013 36) during treatment with RTX. Only one patient was lost to follow-up. Sixteen patients were anti-TNF-na\u00efve and in the remaining patients the TNF-alpha antagonist was stopped due to infectious complications before starting RTX. RTX was combined with a disease modifying drug in 22 (69%) of the cases. Altogether 4 severe infections occurred (9.5\/100 patient years), mainly within the first year of treatment with RTX. Two patients suffered from pneumonia, 1 from a postoperative wound infection, 1 from an ear abscess and bacterial bronchitis. None of our patients with a previous history of bacterial infections of soft tissue, bacterial arthritis or osteomyelitis (n=9) developed recurrent infection. No relapse of a previously diagnosed tuberculosis (n=9) was seen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In this particular high risk population of RA patients, treatment with RTX seems to be an alternative to TNF-alpha-antagonist and has a relatively low rate of recurrent infection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1874312901206010286","type":"journal-article","created":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T07:11:46Z","timestamp":1347952306000},"page":"286-289","update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Rituximab (RTX) as an Alternative to TNF-Alpha Antagonists in Patients with Rheumatoid Arthritis and High Risk of Severe Infections: A Systematic Analysis of the Experience in One Center"],"prefix":"10.2174","volume":"6","author":[{"given":"P","family":"Xanthouli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Sailer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Fiehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"refR1","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","volume":"54","author":"Dixon WG","year":"2006","unstructured":"Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. \n                    Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register \n                    Arthritis Rheum  \n                    2006; \n                    54\n                    (8\n                )\n                    : 2368-76.","journal-title":"Arthritis Rheum"},{"key":"refR2","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"Edwards JC","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, et al. \n                    Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis \n                    N Engl J Med  \n                    2004; \n                    350\n                    (25\n                )\n                    : 2572-81.","journal-title":"N Engl J Med"},{"key":"refR3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","volume":"37","author":"van Vollenhoven RF","year":"2010","unstructured":"van Vollenhoven RF, Emery P, Bingham CO, et al. \n                    Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials \n                    J Rheumatol  \n                    2010; \n                    37\n                    (3\n                )\n                    : 558-67.","journal-title":"J Rheumatol"},{"key":"refR4","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","volume":"62","author":"Gottenberg JE","year":"2010","unstructured":"Gottenberg JE, Ravaud P, Bardin T, et al. \n                    Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry \n                    Arthritis Rheum  \n                    2010; \n                    62\n                    (9\n                )\n                    : 2625-32.","journal-title":"Arthritis Rheum"},{"key":"refR5","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/ard.2008.089664","volume":"68","author":"Chatzidionysious K","year":"2009","unstructured":"Chatzidionysious K, Carli C, van Vollenhofen RF. \n                    Rituximab versus anti-TNF in patients who previously failed one or more anti-TNFs on an observational cohort: the SARASTRA study \n                    Ann Rheum Dis  \n                    2009; \n                    68\n                    (Suppl 3 )\n                    : 445.","journal-title":"Ann Rheum Dis"},{"key":"refR6","first-page":"538","volume":"69","author":"Gomez-Reino J","year":"2009","unstructured":"Gomez-Reino J, Sanmarti R, Romero AB, Monclus L. \n                    Switching to riruximab vs TNF-inhibitor cycling in patients with an inadequate response to TNF-inhibitors: the MIRAR study \n                    Ann Rheum Dis  \n                    2009; \n                    69\n                    ( Suppl 3)\n                    : 538.","journal-title":"Ann Rheum Dis"},{"key":"refR7","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","volume":"69","author":"Finckh A","year":"2010","unstructured":"Finckh A, Ciurea A, Brulhart L, et al. \n                    Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? \n                    Ann Rheum Dis  \n                    2010; \n                    69\n                    (2\n                )\n                    : 387-93.","journal-title":"Ann Rheum Dis"},{"key":"refR8","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/ard.2011.151043","volume":"70","author":"Strangfeld A","year":"2011","unstructured":"Strangfeld A, Eveslage M, Schneider M, et al. \n                    Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? \n                    Ann Rheum Dis  \n                    2011; \n                    70\n                    : 1914-20.","journal-title":"Ann Rheum Dis"},{"key":"refR9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","volume":"65","author":"Schiff MH","year":"2006","unstructured":"Schiff MH, Burmester GR, Kent JD, et al. \n                    Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis \n                    Ann Rheum Dis  \n                    2006; \n                    65\n                    (7\n                )\n                    : 889-94.","journal-title":"Ann Rheum Dis"},{"key":"refR10","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/art.23397","volume":"58","author":"Kremer JM","year":"2008","unstructured":"Kremer JM, Genant HK, Moreland LW, et al. \n                    Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate \n                    Arthritis Rheum  \n                    2008; \n                    58\n                    (4\n                )\n                    : 953-63.","journal-title":"Arthritis Rheum"},{"key":"refR11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"Genovese MC","year":"2008","unstructured":"Genovese MC, Schiff M, Luggen M, et al. \n                    Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy \n                    Ann Rheum Dis  \n                    2008; \n                    67\n                    (4\n                )\n                    : 547-.","journal-title":"Ann Rheum Dis"},{"key":"refR12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jbspin.2010.01.008","volume":"77","author":"Toussirot E","year":"2010","unstructured":"Toussirot E, Pertuiset E, Sordet C, et al. \n                    Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice \n                    Joint Bone Spine  \n                    2010; \n                    77\n                    : 142-5.","journal-title":"Joint Bone Spine"}],"container-title":["The Open Rheumatology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V6\/TORJ-6-286\/TORJ-6-286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V6\/TORJ-6-286\/TORJ-6-286.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrheumatologyjournal.com\/contents\/volumes\/V6\/TORJ-6-286\/TORJ-6-286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:10:34Z","timestamp":1761559834000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrheumatologyjournal.com\/VOLUME\/6\/PAGE\/286\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,7]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,9,7]]}},"alternative-id":["TORJ-6-286"],"URL":"https:\/\/doi.org\/10.2174\/1874312901206010286","relation":{},"ISSN":["1874-3129"],"issn-type":[{"value":"1874-3129","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2012-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-09-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}